Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Company Overview

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Key Stats

• Today's Range: $0.20 to $0.27
• 50-Day Range: $0.16 to $0.32
• 52-Week Range: $0.15 to $0.47
• Volume: 5,804 shs
• Average Volume: 18,248 shs
• Market Capitalization: $1.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Panbela Therapeutics Stock Analysis - MarketRank™

Panbela Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Panbela Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Panbela Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Panbela Therapeutics has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Panbela Therapeutics does not currently pay a dividend.

Dividend Growth

Panbela Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Panbela Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Panbela Therapeutics has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for PBLA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Panbela Therapeutics is held by insiders.

Percentage Held by Institutions

Only 4.37% of the stock of Panbela Therapeutics is held by institutions.

PBLA Stock Analysis - Frequently Asked Questions

How have PBLA shares performed this year?

Panbela Therapeutics' stock was trading at $0.38 at the start of the year. Since then, PBLA shares have decreased by 32.4% and is now trading at $0.2570.

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($159.00) earnings per share for the quarter, missing analysts' consensus estimates of ($94.20) by $64.80.

When did Panbela Therapeutics' stock split?

Panbela Therapeutics shares reverse split on Thursday, January 18th 2024.The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Panbela Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Panbela Therapeutics investors own include Tesla (TSLA), Recursion Pharmaceuticals (RXRX), Aridis Pharmaceuticals (ARDS), Pacific Biosciences of California (PACB), Ginkgo Bioworks (DNA), Tilray Brands (TLRY) and Agnico Eagle Mines (AEM).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 7/11/2025
• Next Earnings (Estimated): 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBLA
• CIK: 1029125
• Web: www.panbela.com
• Phone: (952) 479-1196
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($71.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -302.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.26
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($18.37) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 4,855,000
• Free Float: 4,855,000
• Market Cap: $1.07 million
• Optionable: Not Optionable
• Beta: 1.34